
Auro Laboratories (AUROLAB) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
75.4M
Gross Profit
23.8M
31.59%
Operating Income
6.5M
8.58%
Net Income
6.8M
8.98%
Balance Sheet Metrics
Total Assets
991.0M
Total Liabilities
561.3M
Shareholders Equity
429.7M
Debt to Equity
1.31
Cash Flow Metrics
Revenue & Profitability Trend
Auro Laboratories Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 194.0M | 527.0M | 522.6M | 504.4M | 529.3M |
Cost of Goods Sold | 92.1M | 277.6M | 367.3M | 335.8M | 298.4M |
Gross Profit | 101.9M | 249.4M | 155.4M | 168.6M | 231.0M |
Gross Margin % | 52.5% | 47.3% | 29.7% | 33.4% | 43.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 14.8M | 11.9M | 9.9M | 13.2M |
Other Operating Expenses | 43.2M | 85.8M | 58.6M | 54.3M | 58.2M |
Total Operating Expenses | 43.2M | 100.6M | 70.5M | 64.2M | 71.4M |
Operating Income | 23.1M | 95.8M | 33.2M | 36.1M | 102.1M |
Operating Margin % | 11.9% | 18.2% | 6.4% | 7.2% | 19.3% |
Non-Operating Items | |||||
Interest Income | - | 665.0K | 1.0M | 3.5M | 1.8M |
Interest Expense | 10.8M | 7.4M | 8.1M | 8.3M | 4.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 18.8M | 103.5M | 34.5M | 38.7M | 105.1M |
Income Tax | 421.0K | 25.5M | 10.0M | 10.3M | 33.3M |
Effective Tax Rate % | 2.2% | 24.7% | 29.1% | 26.6% | 31.7% |
Net Income | 18.4M | 77.9M | 24.4M | 28.4M | 71.8M |
Net Margin % | 9.5% | 14.8% | 4.7% | 5.6% | 13.6% |
Key Metrics | |||||
EBITDA | 40.6M | 121.7M | 53.3M | 56.7M | 120.0M |
EPS (Basic) | - | ₹12.50 | ₹3.92 | ₹4.56 | ₹11.52 |
EPS (Diluted) | - | ₹12.50 | ₹3.92 | ₹4.56 | ₹11.52 |
Basic Shares Outstanding | - | 6232500 | 6232500 | 6232500 | 6232500 |
Diluted Shares Outstanding | - | 6232500 | 6232500 | 6232500 | 6232500 |
Income Statement Trend
Auro Laboratories Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 3.0K | 9.9M | 17.9M | 52.1M | 108.2M |
Short-term Investments | 84.5M | 4.7M | 28.6M | 65.7M | 30.0M |
Accounts Receivable | 93.9M | 133.9M | 124.0M | 136.1M | 73.0M |
Inventory | 36.7M | 82.4M | 117.6M | 42.5M | 25.5M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 215.1M | 308.5M | 356.6M | 376.3M | 281.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 210.6M | 16.5M | 16.5M | 16.5M | 16.5M |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 775.8M | 548.8M | 203.3M | 173.3M | 137.4M |
Total Assets | 991.0M | 857.3M | 559.9M | 549.6M | 418.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 62.1M | 62.0M | 114.8M | 48.6M | 57.5M |
Short-term Debt | 119.3M | 78.7M | 44.0M | 121.2M | 7.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 34.0M | 8.3M | 11.9M | 16.4M | 16.7M |
Total Current Liabilities | 216.4M | 239.3M | 181.3M | 201.3M | 92.4M |
Non-Current Liabilities | |||||
Long-term Debt | 330.9M | 183.8M | 20.1M | 16.6M | 23.9M |
Deferred Tax Liabilities | 14.0M | 14.6M | 16.5M | 16.5M | 16.8M |
Other Non-Current Liabilities | - | -95.0K | -1.0K | - | - |
Total Non-Current Liabilities | 344.9M | 198.3M | 36.6M | 33.1M | 40.7M |
Total Liabilities | 561.3M | 437.7M | 217.9M | 234.4M | 133.1M |
Equity | |||||
Common Stock | 62.3M | 62.3M | 62.3M | 62.3M | 62.3M |
Retained Earnings | - | 347.5M | 269.5M | 245.1M | 216.8M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 429.7M | 419.7M | 342.0M | 315.2M | 285.8M |
Key Metrics | |||||
Total Debt | 450.1M | 262.4M | 64.1M | 137.8M | 31.6M |
Working Capital | -1.3M | 69.2M | 175.3M | 175.0M | 189.2M |
Balance Sheet Composition
Auro Laboratories Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 18.8M | 103.5M | 34.5M | 38.7M | 105.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 47.3M | 98.4M | -84.6M | -116.5M | -9.9M |
Operating Cash Flow | 74.2M | 211.7M | -39.6M | -71.9M | 98.1M |
Investing Activities | |||||
Capital Expenditures | 20.0K | 0 | 0 | 0 | - |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -7.3M | -31.0M | -11.1M | -10.8M | -33.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 147.1M | 166.2M | 9.1M | 0 | 0 |
Debt Repayment | 0 | -3.3M | -82.7M | -7.3M | -6.6M |
Financing Cash Flow | 187.7M | 195.0M | -156.4M | 103.1M | -2.2M |
Free Cash Flow | -180.5M | -168.3M | -7.9M | -112.0M | 124.4M |
Net Change in Cash | 254.6M | 375.8M | -207.1M | 20.4M | 62.7M |
Cash Flow Trend
Auro Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
85.07
Price to Book
3.65
Price to Sales
9.51
Profitability Ratios
Profit Margin
5.96%
Operating Margin
-8.69%
Return on Equity
4.28%
Return on Assets
1.86%
Financial Health
Current Ratio
0.99
Debt to Equity
104.76
Beta
0.20
Per Share Data
EPS (TTM)
₹2.95
Book Value per Share
₹68.67
Revenue per Share
₹26.41
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
aurolab | 1.6B | 85.07 | 3.65 | 4.28% | 5.96% | 104.76 |
Sun Pharmaceutical | 3.9T | 37.74 | 5.43 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.79 | 10.93 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 47.8B | -13.92 | -21.95 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.8B | 23.75 | 3.28 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 44.3B | 153.95 | 6.28 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.